VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients

Among the 7 patients on VBI-1901 treatment long enough to have 1+ MRI scan at the time of analysis, one partial tumor response and two stable disease observations have occurred as of May 15,...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Massachusetts ,United States ,Canada ,Israel ,Rehovot ,Hamerkaz ,Ottawa ,Ontario ,Canadian ,American ,Prehevbrio Prehevbri ,Brii Biosciences ,Davide Anderson ,Jeff Baxter ,Company Quarterly Reports On Form ,Nasdaq ,American Society Of Clinical Oncology ,Vaccines Inc ,Oncology Center ,Drug Administration ,Clinical Oncology ,Annual Meeting ,Scientific Officer ,Fast Track ,Orphan Drug Designations ,Data Poster Highlights ,Study Arm ,Granulocyte Macrophage Colony Stimulating Factor ,Randomized Phase ,Central Nervous System Tumors ,Patient Enrollment ,Study Design ,Study Data Highlights ,Track Designation ,Orphan Drug Designation ,Accelerated Approval ,Priority Review ,Drug Evaluation ,Biologics Evaluation ,Clinical Trial Endpoints ,Cancer Drugs ,Private Securities Litigation Reform Act ,Nasdaq Capital Market ,Annual Report ,Quarterly Reports ,